Semaglutide efficacy for weight loss
Pro Research Analysisby 
Searched over 200M research papers
Semaglutide Weight Loss Efficacy in Obesity and Overweight Adults
Significant Weight Loss Outcomes with Semaglutide
Multiple large clinical trials and meta-analyses show that semaglutide, a GLP-1 receptor agonist, leads to substantial weight loss in adults with overweight or obesity. In the STEP clinical trial program, once-weekly subcutaneous semaglutide 2.4 mg resulted in average weight reductions of 14.9% to 17.4% over 68 weeks in people without diabetes, with 69–79% of participants achieving at least 10% weight loss and 51–64% achieving at least 15% weight loss, compared to much lower rates with placebo 14. Over two years, the STEP 5 trial found a mean weight loss of 15.2% with semaglutide versus 2.6% with placebo . These results are supported by systematic reviews and meta-analyses, which report mean body weight reductions of around 10–12% compared to placebo in non-diabetic adults 5910.
Long-Term and Sustained Weight Loss
Semaglutide’s weight loss effects are not only significant but also sustained over time. The SELECT trial demonstrated that weight loss continued for 65 weeks and was maintained for up to four years, with a mean reduction of 10.2% at 208 weeks, compared to 1.5% with placebo . This sustained effect was observed across different BMI categories, sexes, and races .
Dose-Response and Administration Route
Higher doses and longer treatment durations are associated with greater weight loss. Subgroup analyses indicate that weekly dosing of 2.0 mg or more is particularly effective, and individuals with higher baseline BMI may experience more pronounced benefits 29. Both subcutaneous and oral formulations of semaglutide have shown positive results for weight loss, with the highest oral dose (14 mg) yielding the best outcomes 68.
Comparison with Other Treatments
Semaglutide outperforms other anti-obesity medications, such as liraglutide, in head-to-head trials. For example, at 52 weeks, semaglutide at doses of 0.2 mg or higher led to significantly greater weight loss (11.2–13.8%) compared to liraglutide (7.8%) and placebo (2.3%) . These findings have contributed to the approval of semaglutide (Wegovy) for chronic weight management .
Additional Health Benefits and Safety Profile
Beyond weight loss, semaglutide improves cardiometabolic risk factors, including blood pressure, lipid profiles, and markers of inflammation, and enhances physical function and quality of life 1410. The most common side effects are mild-to-moderate gastrointestinal symptoms, such as nausea and diarrhea, which are generally transient. Serious adverse events are less frequent with semaglutide than with placebo, but discontinuation rates due to side effects are higher, especially in those with lower BMI 1379+1 MORE.
Conclusion
Semaglutide is highly effective for weight loss in adults with overweight or obesity, producing clinically meaningful and sustained reductions in body weight. Its benefits extend to improvements in metabolic health, and it is generally well tolerated, with gastrointestinal symptoms being the most common side effect. These findings support semaglutide as a leading pharmacological option for chronic weight management.
Sources and full results
Most relevant research papers on this topic